Skip to main content
. 2018 Oct 5;15(10):2178. doi: 10.3390/ijerph15102178

Table 2.

Risk indicators of metabolic syndrome and cardiovascular diseases over the three study stages.

Indicators MS in 2006–2008 MS in 2009–2011 MS in 2012–2014
n (%) n (%) n (%)
BMI
<24 942 (11.14) 1145 (14.13) 1359 (17.64)
24–26.9 978 (33.53) 1280 (41.78) 1483 (45.84)
≥27 976 (67.17) 1161 (70.02) 1441 (76.49)
Waist (cm)
<80(F); <90(M) 1582 (14.37) 1989 (18.41) 2300 (22.08)
Otherwise 1314 (72.24) 1597 (79.06) 1983 (82.28)
Fasting glucose (mg/dL)
<100 657 (7.69) 743 (9.68) 768 (11.34)
≥100 2239 (52.24) 2843 (55.24) 3515 (58.10)
Triglyceride (mg/dL)
<150 1475 (13.98) 1836 (17.73) 2305 (22.62)
≥150 1421 (62.52) 1750 (70.91) 1978 (75.09)
HDL (mg/dL)
≥40 (M); ≥50(F) 2367 (22.47) 3213 (27.85) 3807 (33.22)
Otherwise 529 (23.09) 373 (28.98) 476 (34.87)
LDL (mg/dL)
<130 1771 (19.19) 2372 (24.67) 2359 (27.98)
≥130 1125 (31.28) 1214 (37.81) 1924 (43.79)
TC (mg/dL)
<200 1340 (16.85) 1650 (21.56) 1960 (27.15)
200–239 1156 (29.44) 1463 (35.13) 1775 (40.10)
≥240 400 (42.24) 473 (47.02) 548 (46.44)
Hypertension
Normal 1088 (10.59) 1537 (15.09) 1911 (19.47)
High normal 975 (63.93) 1109 (72.82) 1210 (74.46)
Phase 1 679 (80.26) 779 (83.76) 940 (82.89)
Phase 2–3 147 (84.48) 153 (86.44) 217 (88.21)
Other 7 (77.78) 8 (88.89) 5 (71.43)
Medicine
Antihyperglycemic drug
Yes 188 (100.00) 282 (100.00) 372 (100.00)
No 2708 (21.43) 3304 (26.34) 3911 (31.41)
Antihyperlipidemic drug
Yes 184 (100.00) 300 (100.00) 410 (100.00)
No 2712 (21.45) 3286 (26.24) 3873 (31.20)
Antihypertensive drug
Yes 733 (100.00) 995 (100.00) 1237 (100.00)
No 2163 (17.89) 2591 (21.90) 3046 (26.29)
Framingham CVD score
Mean (standard deviation) 0.014 (0.015) 0.014 (0.014) 0.015 (0.016)
Medium 0.009 0.009 0.010